ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Utilization of Hepatitis C Positive Organs in Kidney Transplantation

J. Mandel, U. Kaszubski, A. Freeman, L. Hutchinson, M. Janusek, C. Reuter, C. Velasco, B. Wise, S. Anders, E. Bugeaud

Ochsner Medical Center, New Orleans, LA

Meeting: 2020 American Transplant Congress

Abstract number: A-042

Keywords: Donation, Glomerular filtration rate (GFR), Hepatitis C, Kidney transplantation

Session Information

Session Name: Poster Session A: Kidney Deceased Donor Selection

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: The efficacy of direct acting antivirals (DAAs) in HCV has cleared the path for the use of HCV positive donor kidneys into negative recipients. There is limited data, however, in this population regarding transplant-related outcomes and optimal induction immunosuppression. The purpose of this study is to assess the efficacy and safety of HCV (+) donor kidney transplantation in HCV (-) recipients.

*Methods: This is a single-center, retrospective cohort study comparing outcomes of adult HCV (-) kidney recipients who received HCV (+) vs (-) donor organs from November 2018 to July 2019. Recipients who were HCV NAT+ at time of transplant were excluded. The primary outcome was renal function at 3 months. Other outcomes included renal function at 6 months, HCV clearance after treatment, and incidence of rejection and infections. A sub-group analysis of the HCV (+) cohort compared differences in outcomes between alemtuzumab and anti-thymocyte globulin (rATG) for induction.

*Results: Sixty patients received HCV (-), 35 patients received HCV (+) kidneys, of which 26 seroconverted post-transplant. At month 1, eGFR was significantly higher in the HCV (+) group. This difference was maintained through the study period, although did not reach statistical significance. There was no difference in survival, rejection, or infections. Within the HCV (+) group, similar outcomes were observed between those that received alemtuzumab (n = 22) vs rATG (n = 13). The average time to HCV treatment was 52 days post-transplant, and all patients received DAA therapy. Majority of patients achieved SVR at 4 weeks.

*Conclusions: Our results show that kidney transplantation from HCV (+) donors into negative recipients is practical. Utilization of these organs as standard of care among transplant centers can expand the donor pool, thus increasing the number of organs available. We were able to successfully obtain DAA medications in a timely manner for all patients. Further analysis of outcomes beyond 6 months will show the long-term effects of HCV (+) donor organs over time. Use of alemtuzumab and rATG in the HCV (+) group resulted in satisfactory outcomes, highlighting that both agents can be utilized for induction in this patient population.

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Mandel J, Kaszubski U, Freeman A, Hutchinson L, Janusek M, Reuter C, Velasco C, Wise B, Anders S, Bugeaud E. Utilization of Hepatitis C Positive Organs in Kidney Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/utilization-of-hepatitis-c-positive-organs-in-kidney-transplantation/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences